KABRA DRUGS LTD.

Aanjaay Industries Limited (formerly Kabra Drugs Limited) has announced its 37th Annual General Meeting (AGM) to be held on September 30, 2026, at 9:00 AM in Chennai. The company will present its audited financial statements for the fiscal year 2025-2026 and discuss the appointment of a director retiring by rotation. Key agenda items include the appointment of Ms. Moonam Kapoor as a Non-Executive Independent Director for a five-year term and the reappointment of Mrs. Twinkle Agarwal as the Secretarial Auditor. The Annual Report has been dispatched to shareholders.

Aanjaay Industries Limited, formerly known as Kabra Drugs Limited, has issued a notice for its 37th Annual General Meeting (AGM) to be held on Wednesday, September 30, 2026, at 09:00 A.M. in Chennai. The meeting agenda includes the adoption of the Audited Financial Statement for the financial year ended March 31, 2026, and the re-appointment of a director retiring by rotation. Additionally, the company will consider the appointment of Ms. Moonam Kapoor as a Non-Executive Independent Director for a term of five years and Mrs. Twinkle Agarwal as the Secretarial Auditor for five financial years.

Kabra Drugs Ltd (now Aanjaay Industries Limited) has announced the book closure period from September 24, 2026, to September 30, 2026, inclusive, for its upcoming Annual General Meeting (AGM) scheduled for September 30, 2026. The company has also detailed the schedule for e-voting, with a cut-off date of September 23, 2026. Remote e-voting will commence on September 27, 2026, and conclude on September 29, 2026. The notice provides contact details for the e-voting coordinator, Mr. K.N. Anand, Director.

Kabra Drugs Ltd has appointed Mrs. Twinkle Agarwal, a Practicing Company Secretary, as the Secretarial Auditor for the company. This appointment is to comply with the Companies Act, 2013 and SEBI Listing Regulations. The audit will cover the financial years from 2026-2027 to 2027-2031. Mrs. Agarwal is a Member of the Institute of Company Secretaries of India with expertise in corporate laws and compliance.

Kabra Drugs Ltd has appointed M/s Karthik L & Associates, Chartered Accountants, as the Internal Auditor for the Financial Year 2026-2027. This appointment is in continuation of the board meeting outcome dated September 2, 2026, and complies with SEBI Listing Regulations and the Companies Act, 2013. Karthik L & Associates, led by Karthik Loganathan, brings diversified experience in Internal Audit and Statutory Audit across various industries. The firm's office is located in Chennai, and the auditor has extensive experience in financial management, auditing, and compliance.

Kabra Drugs Ltd's Board of Directors met on September 2, 2026, approving key corporate actions. The board sanctioned the Director's Report and Corporate Governance Report for the fiscal year ending March 31, 2026. They also approved the notice for the 37th Annual General Meeting (AGM) scheduled for September 30, 2026, in Chennai. The meeting will include the re-appointment of director Mr. Kuniamuthur Nanjappan Anand and the appointment of Ms. Moonam Kapoor as a new director. Additionally, M/s Karthik L & Associates were appointed as Internal Auditors for FY 2026-2027, and Mrs. Twinkle Agarwal was appointed as Secretarial Auditor for five years.

Kabra Drugs Ltd has officially changed its registered office from Indore, Madhya Pradesh to Chennai, Tamil Nadu. The relocation, effective August 28, 2026, was approved by the Board of Directors and the Regional Director & Registrar of Companies. This move signifies a significant administrative change for the company, with all future correspondence to be directed to the new Chennai address. The company's CIN is L21002TN1989PLC197216, and it was incorporated on August 22, 1989. The change involved altering the Memorandum of Association to shift the registered office from Madhya Pradesh to Tamil Nadu.

Kabra Drugs Ltd has announced a Board of Directors meeting scheduled for September 2, 2026. The meeting will primarily focus on approving the Director's Report and Corporate Governance Report for the financial year ending March 31, 2026. Key agenda items include the closure of the Register of Members and Share Transfer Books for the upcoming Annual General Meeting (AGM), fixing the AGM date, time, and venue, and appointing a scrutinizer. The board will also consider the re-appointment of Director Mr. Kuniamuthur Nanjappan Anand and the appointment of Internal Auditors for FY 2026-2027, as well as recommend the appointment of Ms. Moonam Kapoor as a Director and the Secretarial Auditor for a five-year term.

Kabra Drugs Ltd has announced the reconstitution of its Board of Directors and various committees, effective August 12th, 2026. The changes align with Regulation 30 of the SEBI (LODR) Regulations, 2015. The Board now includes Nanjappan Aravind as Executive Director, Managing Director & Chairperson, Kuniamuthur Nanjappan Anand as Executive Director, and Nikita Sinha, Ritu Tiwari, and Moonam Kapoor as Non-Executive Independent Directors. Key committees, including the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee, have also seen their compositions updated with specific members assigned as chairpersons and members.

Kabra Drugs Ltd announced the resignation of Ms. Anand Anitha as a Director of the company, effective August 12, 2026. The decision was taken based on the recommendation of the Nomination and Remuneration Committee and Audit Committee, and noted by the Board of Directors. The resignation is due to personal reasons, and Ms. Anitha has confirmed there are no other material reasons. She has also confirmed that there are no other directorships or board committee memberships in other listed entities.